Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)

PURPOSE: INVICOST, a medico-economic analysis, compared costs of managing treatment-naive patients with diabetic macular edema (DME) receiving intravitreal injections (IVIs) of aflibercept (AFL), dexamethasone implant (DXI) or ranibizumab (RAN) over 1 year. METHODS: Healthcare resource use and assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gascon, Pierre, Borget, Isabelle, Comet, Alban, Carton, Laurence, Matonti, Frédéric, Dupont-Benjamin, Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109236/
https://www.ncbi.nlm.nih.gov/pubmed/34284605
http://dx.doi.org/10.1177/11206721211033480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109236/
https://www.ncbi.nlm.nih.gov/pubmed/34284605
http://dx.doi.org/10.1177/11206721211033480

Ejemplares similares